News for Enanta Pharmaceuticals, Inc. (ENTA)

[url="]Enanta Pharmaceuticals, Inc.[/url] (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections

[url="]Enanta Pharmaceuticals, Inc.[/url] (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and imm

Enanta Pharmaceuticals (ENTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

On February 12, 2025, [Jay Luly](https://www.gurufocus.com/insider/44166/jay-luly), President and Chief Executive Officer of Enanta Pharmaceuticals Inc, purchas

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 9.48% and 5.93%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Enanta stock touches 52-week low at $5.68 amid market challenges

[url="]Enanta Pharmaceuticals, Inc[/url]. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and im

Pfizer prevails in Enanta patent case over Covid-19 drug

Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Enanta Pharmaceuticals CEO sells $41,444 in stock

Enanta Pharmaceuticals, Inc. (ENTA), a clinical-stage biotechnology company, Monday announced positive topline results from the Phase 2 study evaluating zelicapavir for the treatment of respiratory syncytial virus (RSV).

[url="]Enanta Pharmaceuticals, Inc.[/url] (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and imm

California-based Bolt Projects Holdings, Inc. (BSLK) is up over 233 percent in Friday's pre-market trading. The following are some of the other stocks making big moves in Friday's pre-market trading.

Zoom, Agilent, Woodward, and more set to report earnings Monday

As per Fortune Business Insights’ report, the respiratory syncytial virus therapeutics Market share sector attained a worth of USD 609.2 Million in 2020. Forecasts indicate a promising path…

ArriVent BioPharma adds Kristine Peterson to its Board

/PRNewswire/ -- The "Antibiotic Resistance Markets - Therapeutics by Pathogen and Therapy Type. With Situation Analysis, Executive & Investor Guides &...

Read Equities Research Analysts’ Downgrades for June 3rd (ANSLY, AON, BLRX, BMY, CNTA, CNX, ENTA, FGBI, GHL, HSTM) at ETF Daily News

Read Stock Analysts’ Upgrades for May 31st (ACTD, ADTH, ADV, AKUS, ALNA, AMPE, AMPG, APTO, ENTA, INFY) at ETF Daily News